<DOC>
	<DOCNO>NCT00514813</DOCNO>
	<brief_summary>To assess incidence rate Treatment Emergent Adverse Events ( TEAEs ) 2 year patient treat Dynepo .</brief_summary>
	<brief_title>Dynepo Long-Term Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Patients complete Dynepo study SPD490301 . 2 . Patients continue require epoetin ( EPO ) treatment Hb level 10g/dL Weeks 16 24 study SPD490301 . 1 . Withdrawal , Week 24 , study SPD490301 . 2 . Pregnant lactating woman . 3 . Uncontrolled hypertension . 4 . Thrombocytopenia ( platelet count &lt; 75,000/mm3 ) . 5 . Active bleeding disorder ( diathesis ) ( example , gastrointestinal bleeding genitourinary tract bleed ) . 6 . Treatment immunosuppressive drug ( corticosteroid chronic condition ) 30 day immediately prior enrolment study . 7 . Androgen therapy 30 day immediately prior enrolment study . 8 . Known Human Immunodeficiency Virus ( HIV ) infection . 9 . History hypersensitivity Dynepo . 10 . Known Ab EPO .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>